Microparticles as biomarkers of vascular dysfunction in metabolic syndrome and its individual components

Current Vascular Pharmacology

Volumn 12, Issue 3, 2014, Pages 483-492

  Agouni, Abdelali ^a   Andriantsitohaina, Ramaroson ^b,c,d   Martinez, Maria C ^b,c  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b LUNAM Universite   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Diabetes; Endothelium; Extracellular vesicles; Hypertension; Obesity

Indexed keywords

EPROSARTAN; GLYCOSYLATED HEMOGLOBIN; LIPOCORTIN 5; LOSARTAN; METFORMIN; PIOGLITAZONE; PRAVASTATIN; SIMVASTATIN;

ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NITROSATIVE STRESS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; RISK FACTOR;

EID: 84922392560     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666140423223148     Document Type: Article

References (81)

1. [1] Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13(3): 269-88.
2. [2] Tual-Chalot S, Leonetti D, Andriantsitohaina R, Martinez MC. Microvesicles: intercellular vectors of biological messages. Mol Interv 2011; 11(2): 88-94.
3. [3] Martinez MC, Tual-Chalot S, Leonetti D, Andriantsitohaina R. Microparticles: targets and tools in cardiovascular disease. Trends Pharmacol Sci 2011; 32(11): 659-65.
4. [4] Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010; 107(9): 1047-57.
5. [5] Baron M, Leroyer AS, Majd Z, et al. PPARalpha activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. Atherosclerosis 2011; 218(1): 69-76.
6. [6] D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 2012; 26(12): 1287-99.
7. [7] Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: from biogenesis and secretion to biological function. Immunol Lett 2006; 107(2): 102-8.
8. [8] Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 2000; 45(3): 528-37.
9. [9] Miguet L, Pacaud K, Felden C, et al. Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization. Proteomics 2006; 6(1): 153-71.
10. [10] Smalley DM, Root KE, Cho H, Ross MM, Ley K. Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb Haemost 2007; 97(1): 67-80.
11. [11] Nomura S, Inami N, Shouzu A, Urase F, Maeda Y. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus. Platelets 2009; 20(6): 406-14.
12. [12] Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106(19): 2442-7.
13. [13] Boon RA, Vickers KC. Intercellular Transport of MicroRNAs. Arterioscler Thromb Vasc Biol 2013; 33(2): 186-92.
14. [14] Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol 2008; 173(4): 1210-9.
15. [15] Boulanger CM, Scoazec A, Ebrahimian T, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104(22): 2649-52.
16. [16] Preston RA, Jy W, Jimenez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003; 41(2): 211-7.
17. [17] Omoto S, Nomura S, Shouzu A, Nishikawa M, Fukuhara S, Iwasaka T. Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus. Diabetologia 2002; 45(4): 550-5.
18. [18] Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77(12): 2641-8.
19. [19] Mostefai HA, Meziani F, Mastronardi ML, et al. Circulating microparticles from patients with septic shock exert protective role in vascular function. Am J Respir Crit Care Med 2008; 178(11): 1148-55.
20. [20] La Vignera S, Condorelli R, Vicari E, D'Agata R, Calogero AE. Arterial erectile dysfunction: reliability of new markers of endothelial dysfunction. J Endocrinol Invest 2011; 34(10): e314-20.
21. [21] Csongradi E, Nagy B, Jr., Fulop T, et al. Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients. Thromb Haemost 2011; 106(4): 683-92.
22. [22] Chen J, Chen S, Chen Y, et al. Circulating endothelial progenitor cells and cellular membrane microparticles in db/db diabetic mouse: possible implications in cerebral ischemic damage. Am J Physiol Endocrinol Metab 2011; 301(1): E62-71.
23. [23] Chen Y, Feng B, Li X, Ni Y, Luo Y. Plasma endothelial microparticles and their correlation with the presence of hypertension and arterial stiffness in patients with type 2 diabetes. J Clin Hypertens (Greenwich) 2012; 14(7): 455-60.
24. [24] Jenkins NT, Padilla J, Boyle LJ, Credeur DP, Laughlin MH, Fadel PJ. Disturbed blood flow acutely induces activation and apoptosis of the human vascular endothelium. Hypertension 2013; 61(3): 615-21.
25. [25] Agouni A, Mostefai HA, Porro C, et al. Sonic hedgehog carried by microparticles corrects endothelial injury through nitric oxide release. FASEB J 2007; 21(11): 2735-41.
26. [26] Soleti R, Benameur T, Porro C, Panaro MA, Andriantsitohaina R, Martinez MC. Microparticles harboring Sonic Hedgehog promote angiogenesis through the upregulation of adhesion proteins and proangiogenic factors. Carcinogenesis 2009; 30(4): 580-8.
27. [27] Soleti R, Lauret E, Andriantsitohaina R, Martinez MC. Internalization and induction of antioxidant messages by microvesicles contribute to the antiapoptotic effects on human endothelial cells. Free Radic Biol Med 2012; 53(11): 2159-70.
28. [28] Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468): 1415-28.
29. [29] Fulop T, Tessier D, Carpentier A. The metabolic syndrome. Pathol Biol (Paris) 2006; 54(7): 375-86.
30. [30] Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110(10): 1245-50.
31. [31] Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28(11): 2745-9.
32. [32] Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782-7.
33. [33] Chew GT, Gan SK, Watts GF. Revisiting the metabolic syndrome. Med J Aust 2006; 185(8): 445-9.
34. [34] Sesti G. Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab 2006; 20(4): 665-79.
35. [35] Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112(20): 3066-72.
36. [36] Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology (Bethesda) 2005; 20: 22-7.
37. [37] Wang JM, Su C, Wang Y, et al. Elevated circulating endothelial microparticles and brachial-ankle pulse wave velocity in well- controlled hypertensive patients. J Hum Hypertens 2009; 23(5): 307-15.
38. [38] Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis 2004; 18(3): 177-85.
39. [39] Huang PH, Huang SS, Chen YH, et al. Increased circulating CD31+/annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens 2010; 28(8): 1655-65.
40. [40] Lee CW, Huang PH, Huang SS, et al. Decreased circulating endothelial progenitor cell levels and function in essential hypertensive patients with electrocardiographic left ventricular hypertrophy. Hypertens Res 2011; 34(9): 999-1003.
41. [41] Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-72.
42. [42] Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004; 164(19): 2126-34.
43. [43] Giannotti G, Doerries C, Mocharla PS, et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension 2010; 55(6): 1389-97.
44. [44] Amabile N, Guerin AP, Leroyer A, et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005; 16(11): 3381-8.
45. [45] Lopez Andres N, Tesse A, Regnault V, et al. Increased microparticle production and impaired microvascular endothelial function in aldosterone-salt-treated rats: protective effects of polyphenols. PLoS One 2012; 7(7): e39235.
46. [46] Labios M, Martinez M, Gabriel F, Guiral V, Munoz A, Aznar J. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. Am J Hypertens 2004; 17(9): 757-63.
47. [47] Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. Long- term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2005; 115(4): 277-85.
48. [48] Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002; 51(9): 2840-5.
49. [49] Feng B, Chen Y, Luo Y, Chen M, Li X, Ni Y. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis 2010; 208(1): 264-9.
50. [50] Nomura S, Inami N, Kimura Y, et al. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 2007; 21(1): 38-44.
51. [51] Koga H, Sugiyama S, Kugiyama K, et al. Elevated levels of VE- cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005; 45(10): 1622-30.
52. [52] Bernard S, Loffroy R, Serusclat A, et al. Increased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT). Atherosclerosis 2009; 203(2): 429-35.
53. [53] Tsimerman G, Roguin A, Bachar A, Melamed E, Brenner B, Aharon A. Involvement of microparticles in diabetic vascular complications. Thromb Haemost 2011; 106(2): 310-21.
54. [54] Ogata N, Nomura S, Shouzu A, Imaizumi M, Arichi M, Matsumura M. Elevation of monocyte-derived microparticles in patients with diabetic retinopathy. Diabetes Res Clin Pract 2006; 73(3): 241-8.
55. [55] Ogata N, Imaizumi M, Nomura S, et al. Increased levels of platelet-derived microparticles in patients with diabetic retinopathy. Diabetes Res Clin Pract 2005; 68(3): 193-201.
56. [56] Esposito K, Maiorino MI, Di Palo C, et al. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial. Diabetes Obes Metab 2011; 13(5): 439-45.
57. [57] Nomura S, Omoto S, Yokoi T, et al. Effects of miglitol in platelet- derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus. Int J Gen Med 2011; 4: 539-45.
58. [58] Shimazu T, Inami N, Satoh D, et al. Effect of acarbose on platelet- derived microparticles, soluble selectins, and adiponectin in diabetic patients. J Thromb Thrombolysis 2009; 28(4): 429-35.
59. [59] Sommeijer DW, Joop K, Leyte A, Reitsma PH, ten Cate H. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost 2005; 3(6): 1168-71.
60. [60] Pirro M, Schillaci G, Paltriccia R, et al. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 26(11): 2530-5.
61. [61] Nomura S, Takahashi N, Inami N, et al. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis 2004; 174(2): 329-35.
62. [62] Nomura S, Taniura T, Shouzu A, et al. Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients. Int J Gen Med 2012; 5: 535-40.
63. [63] Ferreira AC, Peter AA, Mendez AJ, et al. Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. Circulation 2004; 110(23): 3599-603.
64. [64] Chan DC, Pang J, Romic G, Watts GF. Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. Curr Atheroscler Rep 2013; 15(3): 309.
65. [65] Funada J, Sekiya M, Hamada M, Hiwada K. Postprandial elevation of remnant lipoprotein leads to endothelial dysfunction. Circ J 2002; 66(2): 127-32.
66. [66] Bae JH, Schwemmer M, Lee IK, et al. Postprandial hypertriglyceridemia-induced endothelial dysfunction in healthy subjects is independent of lipid oxidation. Int J Cardiol 2003; 87(2-3): 259-67.
67. [67] Gunduz Z, Dursun I, Tulpar S, et al. Increased endothelial microparticles in obese and overweight children. J Pediatr Endocrinol Metab 2012; 25(11-12): 1111-7.
68. [68] Esposito K, Ciotola M, Schisano B, et al. Endothelial microparticles correlate with endothelial dysfunction in obese women. J Clin Endocrinol Metab 2006; 91(9): 3676-9.
69. [69] Morel O, Luca F, Grunebaum L, et al. Short-term very low-calorie diet in obese females improves the haemostatic balance through the reduction of leptin levels, PAI-1 concentrations and a diminished release of platelet and leukocyte-derived microparticles. Int J Obes (Lond) 2011; 35(12): 1479-86.
70. [70] Agouni A, Ducluzeau PH, Benameur T, et al. Microparticles from patients with metabolic syndrome induce vascular hypo-reactivity via Fas/Fas-ligand pathway in mice. PLoS One 2011; 6(11): e27809.
71. [71] Helal O, Defoort C, Robert S, et al. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr Metab Cardiovasc Dis 2011; 21(9): 665-71.
72. [72] Arteaga RB, Chirinos JA, Soriano AO, et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 2006; 98(1): 70-4.
73. [73] Ueba T, Haze T, Sugiyama M, et al. Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thromb Haemost 2008; 100(2): 280-5.
74. [74] Chironi G, Simon A, Hugel B, et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 2006; 26(12): 2775-80.
75. [75] Grant R, Ansa-Addo E, Stratton D, et al. A filtration-based protocol to isolate human plasma membrane-derived vesicles and exosomes from blood plasma. J Immunol Methods 2011; 371(1-2): 143-51.
76. [76] Gordon C, Gudi K, Krause A, et al. Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am J Respir Crit Care Med 2011; 184(2): 224-32.
77. [77] Goichot B, Grunebaum L, Desprez D, et al. Circulating procoagulant microparticles in obesity. Diabetes Metab 2006; 32(1): 82-5.
78. [78] Li CJ, Liu Y, Chen Y, Yu D, Williams KJ, Liu ML. Novel proteolytic microvesicles released from human macrophages after exposure to tobacco smoke. Am J Pathol 2013; 182(5): 1552-62.
79. [79] Huang B, Cheng Y, Xie Q, et al. Effect of 40 mg versus 10 mg of atorvastatin on oxidized low-density lipoprotein, high-sensitivity C-reactive protein, circulating endothelial-derived microparticles, and endothelial progenitor cells in patients with ischemic cardiomyopathy. Clin Cardiol 2012; 35(2): 125-30.
80. [80] Mobarrez F, He S, Broijersen A, et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost 2011; 106(2): 344-52.
81. [81] Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 2010; 36(8): 807-18.